PMC:7696151 / 16608-16865 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"471","span":{"begin":90,"end":93},"obj":"Chemical"},{"id":"472","span":{"begin":163,"end":166},"obj":"Chemical"}],"attributes":[{"id":"A471","pred":"tao:has_database_id","subj":"471","obj":"MESH:D006886"},{"id":"A472","pred":"tao:has_database_id","subj":"472","obj":"MESH:D006886"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ider that the first two described clinical trials, which reported the antiviral effect of HCQ, were on short-term treatments (8 or 16 weeks) and that they used an HCQ dosage of 800 mg/day [17,18]. In contrast, the latter used only 400 mg/day [24], correspon"}